Suttorp MJ, Laarman GJ, Rahel BM, et al. 2006. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II). Circula- tion, 114:921–8. Suzuki T, Kopia G, Hayashi S, et al. 2001. Stent based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circula- tion, 104:1188–93. Urban P, Gershlick AH, Guagliumi G, et al. 2006. Safety of coronary sirolimus-eluting stents in daily practice: one-year follow-up of the e-CYPHER registry. Circulation, 113:1434–41. Van Hout BA, van der Woude T, de Jaegere PP, et al. 1996. Cost-effectiveness of stent implantation versus PTCA: the BENESTENT experience. Semin Interv Cardiol, 1:263–8. Sirolimus-eluting coronary stents Vezina C, Kudelski A, Sehgal SN. 1975. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy pf the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo), 28:721–6. Weisz G, Leon MB, Holmes Dr Jr, et al. 2006. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol, 47:1350–5. Windecker S, Remondino A, Eberli FR, et al. 2005. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med, 353:653–62. Vascular Health and Risk Management 2007:3(2) 201